Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?

Executive Summary

With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.

Advertisement

Related Content

2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
J&J Thinks It Can Win Over Biosimilar Competition
Tentative-Style Approvals Coming For US Biosimilars?
Chances Upped Supreme Court Hears Amgen/Sandoz Biosimilars Suit
Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties
Panel Favors Celltrion Biosimilar; Skeptical On Cost Savings
Woodcock: Biosimilars Program Lacks Funding, Will Explode
US Capitol Capsule: Don't Make Assumptions On Biosimilars Actions, FDA Official Warns
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing
FDA's 1st biosimilar adcomm: a lovefest

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel